Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Gets Serious About Cell Therapy With TiGenix Buy

Executive Summary

Takeda will acquire its Belgian biotech partner, TiGenix, to strengthen its gastro-intestinal portfolio, bolster its regenerative medicines capacity and grow its US specialty care presence.

Advertisement

Related Content

Takeda Secures TiGenix But Investor Shire Concerns Bubble Up
EU Yes For TiGenix Marks Tenth ATMP Approval in Ten Years
Appointments: Changes at SOTIO, Helsinn, Sobi, AMRI, Blade and Vertex
Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business
TiGenix CEO Confident Of European Green Light For Lead Asset
TiGenix The Latest Partner In Takeda Deal Frenzy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100150

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel